- Chromocell Issues Letter to Stockholders from Chief Executive Officer
- Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler
- Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023
- Chromocell to Present at Sidoti Virtual Investor Conference March 13-14
- Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions
- Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million
- Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
More ▼
Key statistics
On Wednesday, Chromocell Therapeutics Corp (CHRO:ASQ) closed at 1.84, 51.82% above the 52 week low of 1.21 set on Apr 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.66 |
---|---|
High | 1.87 |
Low | 1.66 |
Bid | 1.62 |
Offer | 1.87 |
Previous close | 1.84 |
Average volume | 10.88k |
---|---|
Shares outstanding | 5.88m |
Free float | 1.63m |
P/E (TTM) | -- |
Market cap | 10.80m USD |
EPS (TTM) | -1.28 USD |
Data delayed at least 15 minutes, as of May 08 2024.
More ▼